LIPOFLEX PERI EMULSION FOR INFUSION

Introduction

Package Leaflet: Information for the User

Lipoflex peri emulsion for infusion EFG

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again. If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

1. What Lipoflex peri is and what it is used for
2. What you need to know before you use Lipoflex peri
3. How to use Lipoflex peri
4. Possible side effects
5. Storage of Lipoflex peri
6. Contents of the pack and other information

1. What Lipoflex peri is and what it is used for

Lipoflex peri contains liquids and substances called amino acids, electrolytes, and fatty acids that are essential for the growth or recovery of the body. It also contains calories in the form of carbohydrates and fats.

This medicine is given when there is an inability to eat food normally. There are many situations where this can occur, such as during the recovery phases of surgical interventions, trauma, or burns, or when there is an inability to absorb food in the stomach and intestine.

This emulsion can be administered to adults, adolescents, and children over 2 years of age.

2. What you need to know before you use Lipoflex peri

Do not use Lipoflex peri

? if you are allergic to any of the active substances, egg, peanut, or soy or any of the other components of this medicine (listed in section 6),

? this medicine must not be administered to newborns, infants, and children under two years of age.

Also, do not use this medicine if you have any of the following disorders:

? potentially life-threatening blood circulation problems, such as those that can occur in cases of collapse or shock,

? myocardial infarction or stroke,

? severe blood coagulation disorders, risk of bleeding (severe coagulopathy, hemorrhagic diathesis),

? blockage of blood vessels by blood clots or fat (embolism),

? severe liver failure,

? altered bile flow (intrahepatic cholestasis),

? renal failure where dialysis equipment is not available,

? alterations in the body's salt composition,

? fluid deficit or excess water in your body,

? water in your lungs (pulmonary edema),

? severe heart failure,

? certain metabolic disorders, such as:

• too much fat (lipids) in the blood,
• congenital disorders of amino acid metabolism,
• abnormally high blood sugar levels that require more than 6 units of insulin per hour to be controlled,
• metabolic disorders that can occur after surgical interventions or trauma,
• coma of unknown origin,
• insufficient oxygen supply to the tissues,
• abnormally high acid levels in the blood.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting to use Lipoflex peri.

Tell your doctor if:

? you have heart, liver, or kidney problems,

? you have certain types of metabolic disorders, such as diabetes, abnormal blood fat values, and disorders of body fluid and salt composition or acid-base balance.

You will be closely monitored to detect the first signs of an allergic reaction (such as fever, chills, skin rash, or shortness of breath) when you receive this medicine.

Additional monitoring and tests, such as various blood sample tests, will be performed to ensure that your body is adequately assimilating the administered food.

Nursing staff may also take measures to ensure that your body's fluid and electrolyte needs are met. In addition to this medicine, you may receive additional nutrients (food) to fully meet your needs.

Children

This medicine must not be administered to newborns, infants, or children under two years of age.

Using Lipoflex peri with other medicines

Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines.

Lipoflex peri may interact with some medicines. Tell your doctor, pharmacist, or nurse if you are taking or receiving any of the following medicines:

? insulin,

? heparin,

? medicines that prevent unwanted blood clotting, such as warfarin or other coumarin derivatives,

? medicines that promote urine flow (diuretics),

? medicines for treating high blood pressure (ACE inhibitors),

? medicines for treating high blood pressure or heart problems (angiotensin II receptor antagonists),

? medicines used in organ transplantation, such as cyclosporine and tacrolimus,

? medicines for treating inflammation (corticosteroids),

? hormonal preparations that affect your fluid balance (adrenocorticotropic hormone or ACTH).

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. If you are pregnant, you will receive this medicine only if your doctor or pharmacist considers it absolutely necessary for your recovery. There are no data available on the use of Lipoflex peri in pregnant women.

Breastfeeding is not recommended in mothers treated with parenteral nutrition.

Driving and using machines

This medicine is usually administered to patients who are immobilized, e.g., in a hospital or clinic, which excludes the possibility of driving or using machines. However, this medicine itself does not affect the ability to drive or use machines.

Lipoflex peri contains sodium

This medicine contains 1.150 mg of sodium (the main component of table/cooking salt) in each 1.250 ml bag. This is equivalent to 58% of the maximum recommended daily intake of sodium for an adult.

The maximum recommended daily dose of this medicine contains 2.580 mg of sodium (present in table salt). This is equivalent to 129% of the maximum recommended daily intake of sodium for an adult.

Consult your doctor or pharmacist if you need one or more bags per day for a prolonged period, especially if you have been advised to follow a low-salt diet.

3. How to use Lipoflex peri

This medicine is administered by intravenous infusion (drop by drop), i.e., through a small tube directly into a vein. This medicine can be administered through one of your small veins (peripheral) or through one of your large veins (central).

Your doctor or pharmacist will decide what amount of this medicine you need and for how long you will need treatment with it.

Use in children

This medicine must not be administered to newborns, infants, and children under two years of age.

Your doctor will decide what amount of this medicine your child needs and for how long your child will need treatment with this medicine.

If you use more Lipoflex peri than you should

If you have received too much of this medicine, you may suffer from the so-called "overload syndrome" and the following symptoms:

? excess fluid and electrolyte disturbances,

? water in your lungs (pulmonary edema),

? loss of amino acids through the urine and disturbances in amino acid balance,

? vomiting, nausea,

? chills,

? high blood sugar levels,

? glucose in urine,

? fluid deficit,

? blood that is much more concentrated than normal (hyperosmolality),

? alteration or loss of consciousness due to extremely high blood sugar levels,

? enlarged liver (hepatomegaly) with or without jaundice,

? enlarged spleen (splenomegaly),

? fat deposits in internal organs,

? abnormal liver function test values,

? reduced red blood cell count (anemia),

? reduced white blood cell count (leukopenia),

? reduced platelet count (thrombocytopenia),

? increased immature red blood cells (reticulocytosis),

? rupture of blood cells (hemolysis),

? bleeding or tendency to bleed,

? disturbances of blood coagulation (as can be seen by changes in bleeding time, coagulation time, prothrombin time, etc.),

? fever,

? high levels of fat in the blood,

? loss of consciousness.

If any of the following symptoms occur, the infusion must be stopped immediately.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects may be serious. If you experience any of the following side effects, tell your doctor immediately, who will stop administering this medicine:

Rare (may affect up to 1 in 1,000 people):

? allergic reactions, such as skin reactions, shortness of breath, swelling of the lips, mouth, and throat, difficulty breathing.

Other side effects include:

Common (may affect up to 1 in 10 people):

? irritation or inflammation of the veins (phlebitis, thrombophlebitis).

Uncommon (may affect up to 1 in 100 people):

? nausea, vomiting, loss of appetite.

Rare (may affect up to 1 in 1,000 people):

? increased tendency of blood to clot,

? bluish discoloration of the skin,

? shortness of breath,

? headache,

? flushing,

? redness of the skin (erythema),

? sweating,

? chills,

? feeling of cold,

? high body temperature,

? drowsiness,

? pain in the chest, back, bones, or lumbar region,

? decreased or increased blood pressure.

Very rare (may affect up to 1 in 10,000 people):

? abnormally high sugar or fat levels in the blood,

? high levels of acidic substances in your blood,

? an excess of lipids can cause overload syndrome; for more information, see the heading "If you use more Lipoflex peri than you should" in section 3. The symptoms usually disappear when the infusion is stopped.

Frequency not known (cannot be estimated from the available data):

? reduced white blood cell count (leukopenia),

? reduced platelet count (thrombocytopenia),

? disturbances of bile flow (cholestasis).

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet.

You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines (www.notificaRAM.es)

5. Storage of Lipoflex peri

Keep this medicine out of the sight and reach of children.

Do not store above 25°C.

Do not freeze. Discard the bag if it has been accidentally frozen. Keep the bag in the outer packaging to protect it from light.

Do not use this medicine after the expiry date which is stated on the label. The expiry date is the last day of the month stated.

6. Container Contents and Additional Information

Composition ofLipoflex peri

The active principles of the ready-to-use mixture are:

The other components are citric acid monohydrate (for pH adjustment), injectable egg phospholipids, glycerol, sodium oleate, all-rac-alpha-tocopherol, and water for injectable preparations.

Appearance of the product and container contents

The ready-to-use product is an emulsion for infusion, i.e., it is administered through a small tube into a vein.

Lipoflex peri is supplied in flexible multi-chamber bags containing:

• 1,250 ml (500 ml of amino acid solution + 250 ml of fat emulsion + 500 ml of glucose solution),
• 1,875 ml (750 ml of amino acid solution + 375 ml of fat emulsion + 750 ml of glucose solution),
• 2,500 ml (1,000 ml of amino acid solution + 500 ml of fat emulsion + 1,000 ml of glucose solution).

Figure A Figure B

Figure A: The multi-chamber bag is inserted into a protective wrapper. Between the bag and the wrapper are an oxygen absorber and an oxygen indicator; the oxygen absorber package is made of an inert material and contains iron hydroxide.

Figure B: The upper chamber contains a glucose solution, the middle chamber contains a fat emulsion, and the lower chamber contains an amino acid solution.

The glucose and amino acid solutions are clear and colorless to light yellow. The fat emulsion is white and milky.

The upper and middle chambers can be connected to the lower chamber by opening the intermediate seams (peelable seams).

The bag design allows for the mixing of amino acids, glucose, lipids, and electrolytes in a single chamber. When the peelable seams are opened, a sterile mixture is formed that creates an emulsion.

The different container sizes are presented in boxes containing five bags.

Container sizes: 5 x 1,250 ml, 5 x 1,875 ml, and 5 x 2,500 ml

Only some container sizes may be marketed.

Marketing authorization holder:

• Braun Melsungen AG

Carl-Braun-Str. 1 Postal address:

34212 Melsungen, Germany 34209 Melsungen, Germany

Tel.: +49-(0)-5661-71-0

Fax: +49-(0)-5661-71-4567

Manufacturer

• Braun Melsungen AG

Am Schwerzelshof 1

34 212 Melsungen

Germany

For further information on this medicinal product, please contact the local representative of the marketing authorization holder

• Braun Medical, S.A.

Ctra. de Terrassa, 121

08191 Rubí, Spain

This medicinal product is authorized in the Member States of the European Economic Areaand in the United Kingdom (Northern Ireland)under the following names:

Austria Nutriflex Lipid peri B.Braun

Belgium Nutriflex Lipid peri, 32 g/l AA + 64 g/l G, emulsie voor infusie

Denmark Lipoflex peri

Finland Nutriflex Lipid 32/64/40 perifer

Germany Nutriflex Lipid 32/64 peri

Iceland Nutriflex Lipid 32/64 peri

Italy Lipoflex AA32/G64 emulsione per infusione

Luxembourg Nutriflex Lipid 32/64 peri

Netherlands Nutriflex Lipid peri, 32 g/l + 64 g/l, emulsie voor infusie

Norway Lipoflex peri

Poland Lipoflex peri

Romania Lipoflex peri emulsie perfuzabila

Spain Lipoflex peri emulsión para perfusión

Sweden Nutriflex Lipid 32/64/40 perifer

United Kingdom

(Northern Ireland) Lipoflex peri emulsion for infusion

Date of the last revision of this leaflet:

09/2023

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)

______________________________________________________________________________

This information is intended only for healthcare professionals:

No special requirements are necessary for disposal.

Parenteral nutrition products should be visually inspected before use for damage, color changes, and emulsion instability.

Do not use damaged bags. The wrapper, main bag, and peelable seams between the chambers must be intact. Use only if the amino acid and glucose solutions are clear and colorless to light yellow and if the lipid emulsion is homogeneous and has a white, milky color. Do not use if the solutions contain particles.

After mixing the three chambers, do not use if the emulsion shows a color change or signs of phase separation (oil droplets, oil layer). Stop the infusion immediately in case of a color change in the emulsion or signs of phase separation.

Before opening the wrapper, check the color of the oxygen indicator (see Figure A). Do not use if the oxygen indicator changes to a pink color. Use only if the oxygen indicator is yellow.

Preparation of the mixed emulsion

A strict adherence to aseptic handling principles is required.

For opening: open the wrapper starting from the tear notches (Fig. 1). Remove the bag from its protective wrapper. Discard the wrapper, oxygen indicator, and oxygen absorber.

Visually inspect the main bag for leaks. Bags with leaks must be discarded, as their sterility cannot be guaranteed.

Mixing the bag and adding additives

To open and mix the chambers sequentially, roll the bag with both hands, first opening the peelable seam that separates the upper chamber (glucose) from the lower chamber (amino acids) (Fig. 2).

After removing the aluminum foil (Fig. 3), it is possible to add compatible hydrophilic additives through the medication port (Fig. 4) to the clear aqueous solutions. Mix the bag contents well (Fig. 5) and visually inspect the mixture for precipitates (Fig. 6). The solution should only be used if it is transparent.

Then, continue to apply pressure so that the peelable seam that separates the middle chamber (lipids) from the lower chamber (Fig. 7) opens.

The mixture is a homogeneous oil-in-water emulsion with a white, milky color. Once all the chambers have been mixed, it is possible to add compatible additives through the medication port (Fig. 4). Mix the bag contents well (Fig. 8) and visually inspect the mixture (Fig. 9).

The manufacturer may provide, upon request, data on the compatibility of different additives (e.g., electrolytes, trace elements, vitamins) and the corresponding validity periods of these mixtures.

Preparation for infusion

The emulsion should always be brought to room temperature before infusion.

Remove the aluminum foil (Fig. 10) from the infusion port and connect the infusion equipment (Fig. 11). Use a non-ventilated infusion set or close the air vent if a ventilated set is used. Hang the bag from an infusion hook (Fig. 12) and perform the infusion according to the standard technique.

For single use. The container and unused contents should be discarded after use.

Do not reconnect partially used containers.

If filters are used, they must be lipid-permeable (pore size ≥ 1.2 μm).

Validity period after removal of the protective wrapper and after mixing the bag contents

Chemical and physicochemical stability of the amino acid, glucose, and lipid mixture has been demonstrated during use for 7 days at 2-8°C and for 2 additional days at 25°C.

Validity period after additional mixing of compatible additives

From a microbiological point of view, the product should be used immediately after the additional mixing of additives. Otherwise, the storage times during use and the conditions prior to use are the responsibility of the user.

The emulsion should be used immediately after opening the container.

The recommended duration for the infusion of a parenteral nutrition bag is a maximum of 24 hours.

This medicinal product should not be mixed with other medicinal products whose compatibility has not been documented.

This medicinal product should not be administered simultaneously with blood in the same infusion equipment due to the risk of pseudoagglutination.